

**Sister Study Ovarian, Fallopian Tube, and Peritoneal Cancer Outcomes (any behavior)<sup>1</sup> and Characteristics: Data Release 10.1<sup>2</sup>**

	<b>N</b>	<b>% of cohort</b>
<b>Total Cases<sup>3</sup></b>	<b>526</b>	<b>1.0</b>
<b>Timing, Behavior, and Site</b>	<b>N</b>	<b>% of cases</b>
Baseline	204	38.8
Invasive	203	38.6
Ovary	195	37.1
Fallopian tube	3	0.6
Unknown <sup>4</sup>	5	1.0
<i>In situ</i> – Peritoneum	1	0.2
Unknown timing <sup>5</sup> – Invasive – Ovary	30	5.7
Incident	292	55.5
Invasive	291	55.3
Ovary	239	45.4
Fallopian tube	21	4.0
Broad ligament	1	0.2
Peritoneum <sup>6</sup>	11	2.1
Unknown <sup>7</sup>	19	3.6
Uncertain behavior – Ovary	1	0.2
<b>Incident</b>	<b>292</b>	
<b>Race/Ethnicity<sup>8</sup></b>		
Non-Hispanic White	253	86.6
Non-Hispanic Black	23	7.9
Hispanic	10	3.4
Other	6	2.1
<b>Age (in years) at Diagnosis<sup>9</sup></b>		
Under 50	18	6.2
50-64	135	46.2
65 and older	139	47.6
<b>Diagnosis Confirmation<sup>10</sup></b>		
Medical	190	65.1
NDI Plus or death certificate only	35	12.0
None	67	22.9

Characteristic	N	%
<b>Incident – Medically Confirmed</b>	<b>190</b>	
<b>Stage at Diagnosis<sup>11</sup></b>		
I	54	30.0
II	19	10.6
III	88	48.9
IV	19	10.6
Missing, cannot stage	10	

<sup>1</sup> Peritoneal cancer excludes retroperitoneal site of origin. Cancer events are defined by the following ICD10 cancer codes: invasive ovary (C56), invasive fallopian tube (C57.0), invasive broad ligament (C57.1), invasive peritoneum (C48.1, C48.2, C48.8), uncertain behavior of ovary (D39.1), uncertain behavior of peritoneum (D48.4). Other ICD10 cancer codes that may be used when ovary, fallopian tube, broad ligament, or peritoneum are indicated as one of the favored primary sites: invasive female genital organ (C57.9), invasive unspecified site (C80), *in situ* female genital organ (D07.3), *in situ* other site (D09.8), uncertain behavior of female genital organ (D39.8, D39.9), unspecified behavior of genitourinary organ (D49.59).

<sup>2</sup> Data release 10.1 includes outcomes from follow-up phases that closed on or before 10/12/2020, excluding all data from participants who have withdrawn their data from the study [n=4].

<sup>3</sup> Excludes cancer diagnoses where ovarian, fallopian tube, broad ligament, or peritoneal site of origin could not be ruled out, but none are the favored site [n=13]

<sup>4</sup> Unknown site includes ovary or fallopian tube [n=1]; ovary or omentum [n=1]; ovary, fallopian tube, or peritoneum [n=1]; and also includes diagnoses where ovary, fallopian tube, or peritoneum are favored primary site(s) but other site(s) cannot be ruled out [n=2]

<sup>5</sup> Unknown timing represents cases that are unknown if diagnosis at or prior to baseline vs. post-baseline (i.e. incident case)

<sup>6</sup> Includes omentum [n=2]

<sup>7</sup> Unknown site includes reports of ovary or fallopian tube [n=3]; ovary or peritoneum [n=4]; fallopian tube or peritoneum [n=2]; ovary, fallopian tube, or peritoneum [n=4]; and also includes diagnoses where ovary, fallopian tube, or peritoneum are favored primary site(s) but other site(s) cannot be ruled out [n=6]

<sup>8</sup> Race/ethnicity: precedence given to Hispanic ethnicity first, then Black race, then other race, then White race

<sup>9</sup> For those missing age at diagnosis [n=13], age was imputed as the midpoint of the range of plausible ages at diagnosis

<sup>10</sup> Medical confirmation of reported ovarian, fallopian tube, broad ligament, or peritoneal cancer is generally from pathology report but may include other medical documentation; National Death Index (NDI) Plus or death certificate confirmation is specific to cases that do not have medical confirmation

<sup>11</sup> Stage at diagnosis is only available for cases with medical confirmation